Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
The FDA launched PreCheck on Feb. 1, 2026, to speed drug facility approvals, but four of seven fast-tracked drugs faced delays due to safety issues.
The U.S. FDA launched the PreCheck pilot program on February 1, 2026, to accelerate construction and regulatory review of new domestic pharmaceutical facilities, prioritizing critical drugs and innovative designs.
The two-phase approach includes early FDA engagement during planning and pre-application feedback to streamline approvals.
Complementing it, the National Priority Voucher Program offers expedited reviews—targeting decisions in one to two months—for vital drugs.
However, internal documents show at least four of seven fast-tracked drugs faced delays due to safety and efficacy concerns, including a patient death, with some approvals postponed despite initial timelines.
The FDA maintains its commitment to balancing speed with rigorous safety evaluation.
La FDA lanzó PreCheck el 1 de febrero de 2026, para acelerar las aprobaciones de las instalaciones farmacéuticas, pero cuatro de los siete medicamentos acelerados enfrentaron retrasos debido a problemas de seguridad.